Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears
Third To Be Hit With MS Clinical Hold
Adding to a growing pattern within the BTK inhibitor pipeline for multiple sclerosis, the US FDA has placed Merck’s evobrutinib on a partial clinical hold following two liver injury incidents, prompting questions over its ultimate approvability.
You may also be interested in...
The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.
The French firm’s ex-blockbuster multiple sclerosis drug, Aubagio, saw sales more than halve as generics made their mark, prompting the firm to tout recent developments for two pipeline contenders for the disease.
The Swiss behemoth’s top five growth drivers – Vabysmo, Ocrevus, Hemlibra, Evrysdi and Phesgo – are selling well and softening the loss in earnings from products that boomed during COVID-19.